metastatic bone disease
Recently Published Documents


TOTAL DOCUMENTS

586
(FIVE YEARS 85)

H-INDEX

49
(FIVE YEARS 5)

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Mitchell S. Fourman ◽  
Duncan C. Ramsey ◽  
Erik T. Newman ◽  
Marilyn Heng ◽  
Kevin A. Raskin ◽  
...  

Author(s):  
Muhammad Umar Jawad ◽  
Brad H. Pollock ◽  
Barton L. Wise ◽  
Lauren N. Zeitlinger ◽  
Edmond F. O’ Donnell ◽  
...  

2021 ◽  
Vol 64 (6) ◽  
pp. E550-E560
Author(s):  
Annalise Abbott ◽  
Joseph K. Kendal ◽  
Christopher Hewison ◽  
Shannon Puloski ◽  
Michael Monument

2021 ◽  
Vol 103-B (11) ◽  
pp. 1725-1730
Author(s):  
Rachel Baumber ◽  
Craig Gerrand ◽  
Michael Cooper ◽  
William Aston

Aims The incidence of bone metastases is between 20% to 75% depending on the type of cancer. As treatment improves, the number of patients who need surgical intervention is increasing. Identifying patients with a shorter life expectancy would allow surgical intervention with more durable reconstructions to be targeted to those most likely to benefit. While previous scoring systems have focused on surgical and oncological factors, there is a need to consider comorbidities and the physiological state of the patient, as these will also affect outcome. The primary aim of this study was to create a scoring system to estimate survival time in patients with bony metastases and to determine which factors may adversely affect this. Methods This was a retrospective study which included all patients who had presented for surgery with metastatic bone disease. The data collected included patient, surgical, and oncological variables. Univariable and multivariable analysis identified which factors were associated with a survival time of less than six months and less than one year. A model to predict survival based on these factors was developed using Cox regression. Results A total of 164 patients were included with a median survival time of 1.6 years (interquartile range 0.5 to 3.1) after surgery. On multivariable analysis, a higher American Society of Anesthesiologists grade (p < 0.001), a high white cell count (p = 0.002), hyponatraemia (p = 0.001), a preoperative resting heart rate of > 100 bpm (p = 0.052), and the type of primary cancer (p = 0.026) remained significant predictors of reduced survival time. The predictive model developed showed good discrimination and calibration to predict both six- and 12-month survival in patients with metastatic bone disease. Conclusion In addition to surgical and oncological factors, the level of comorbidity and physiological state of the patient has a significant impact on survival in patients with metastatic bone disease. These factors should be considered when assessing the appropriateness of surgical intervention. This is the first study to examine other patient factors alongside surgical and oncological data to identify a relationship between these and survival. Cite this article: Bone Joint J 2021;103-B(11):1725–1730.


2021 ◽  
Vol 12 (10) ◽  
pp. 743-750
Author(s):  
Jennifer Sebghati ◽  
Pendar Khalili ◽  
Panagiotis Tsagkozis

2021 ◽  
Vol 31 (8) ◽  
pp. 1547-1555
Author(s):  
Shinji Tsukamoto ◽  
Costantino Errani ◽  
Akira Kido ◽  
Andreas F. Mavrogenis

Sign in / Sign up

Export Citation Format

Share Document